We are live on ! Find out more
EWTX icon

Edgewise Therapeutics

214 hedge funds and large institutions have $3.72B invested in Edgewise Therapeutics in 2026 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 65 increasing their positions, 66 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 24

69% more call options, than puts

Call options by funds: $18.7M | Put options by funds: $11.1M

23% more capital invested

Capital invested by funds: $3.02B → $3.72B (+$699M)

10% more funds holding in top 10

Funds holding in top 10: 1011 (+1)

8% more funds holding

Funds holding: 199214 (+15)

2% less repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 66

4.57% less ownership

Funds ownership: 115.07%110.5% (-4.6%)

Holders
214
Holders Change
+15
Holders Change %
+7.54%
% of All Funds
2.63%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.14%
New
44
Increased
65
Reduced
66
Closed
24
Calls
$18.7M
Puts
$11.1M
Net Calls
+$7.66M
Net Calls Change
+$6.35M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
$32M +$9.35M +324,097 +47%
FLAM
27
First Light Asset Management
Minnesota
$31.6M -$16.5M -571,855 -36%
Aberdeen Group
28
Aberdeen Group
United Kingdom
$26M +$119K +4,119 +0.5%
Qube Research & Technologies (QRT)
29
Qube Research & Technologies (QRT)
United Kingdom
$26M +$15.3M +529,702 +179%
Victory Capital Management
30
Victory Capital Management
Texas
$24.9M +$1.23M +42,481 +6%
Artisan Partners
31
Artisan Partners
Wisconsin
$20.8M -$1.3M -45,010 -6%
Marshall Wace
32
Marshall Wace
United Kingdom
$20.4M -$967K -33,528 -5%
Goldman Sachs
33
Goldman Sachs
New York
$19.8M -$2.55M -88,552 -12%
Charles Schwab
34
Charles Schwab
California
$18.8M -$435K -15,074 -2%
Northern Trust
35
Northern Trust
Illinois
$18.2M +$488K +16,907 +3%
VPM
36
Vanguard Portfolio Management
Pennsylvania
$17.6M +$16.1M +557,260 New
VFT
37
Vanguard Fiduciary Trust
Pennsylvania
$16.4M +$15M +521,726 New
OM
38
Opaleye Management
Massachusetts
$15.8M
CS
39
Candriam SCA
Luxembourg
$14.1M -$1.55M -53,798 -11%
Citadel Advisors
40
Citadel Advisors
Florida
$13.5M +$8.82M +305,935 +249%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
41
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$12.7M -$6.81M -236,200 -37%
SI
42
Sofinnova Investments
California
$12.2M -$1.48M -51,321 -12%
SCM
43
Squadron Capital Management
Illinois
$11M
Millennium Management
44
Millennium Management
New York
$10.8M +$6.24M +216,431 +171%
N
45
Nuveen
North Carolina
$10.6M +$4.8M +166,317 +98%
PHP
46
Parkman Healthcare Partners
Connecticut
$10.2M -$3.02M -104,862 -25%
SC
47
Stempoint Capital
New York
$9.16M -$2.02M -70,012 -19%
Universal-Beteiligungs- und Servicegesellschaft
48
Universal-Beteiligungs- und Servicegesellschaft
Germany
$8.92M +$344K +11,927 +4%
SCM
49
Sio Capital Management
New York
$8.47M +$909K +31,505 +13%
KCM
50
Kennedy Capital Management
Missouri
$8.32M +$654K +22,695 +9%

EWTX Hedge Fund Activity: Q1 2026 in Review

214 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q1 2026, worth a combined $3.72B — up 23% from $3.02B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new EWTX positions and 24 closed out — a net gain of 20 holders — while 65 added to existing stakes and 66 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $38.9M. The largest seller was Braidwell, cutting an estimated $82.6M.

  • 214 institutional investors held Edgewise Therapeutics (EWTX) as of Q1 2026, up from 199 in Q4 2025.
  • Funds reported $3.72B of Edgewise Therapeutics stock for Q1 2026, up 23% quarter-over-quarter.
  • 44 funds opened new Edgewise Therapeutics positions in Q1 2026 and 24 closed out, a net change of +20 holders.
  • The largest Edgewise Therapeutics buyer in Q1 2026 was Janus Henderson Group, an estimated $38.9M added.
  • The largest Edgewise Therapeutics seller in Q1 2026 was Braidwell, an estimated $82.6M sold.

Based on aggregated 13F filings for Q1 2026.